Flamma
Pharmaceutical ManufacturingLombardy, Italy201-500 Employees
Flamma is a global contract development and manufacturing organization focused on chemistry-driven small molecule APIs, starting materials, and advanced intermediates, offering services from early-stage process development through commercial production. It maintains an integrated network with manufacturing in Italy and strategic facilities in the United States and China, including FDA-inspected cGMP sites in Italy and the United States and a fully owned facility in Dalian, supporting a resilient global supply chain for innovator customers. In the U.S., Flamma USA provides early-stage development capabilities, including high-potency API and controlled-substance handling, complementing its China operations to accelerate timelines and optimize costs. Founded on decades of experience, Flamma presents itself as a CDMO with recognized strengths in expertise, reliability, capabilities, quality, service, and compatibility, seeking to guide complex small-molecule programs from concept to commerce. The company is advancing its global infrastructure, including a new cGMP plant in Dalian as part of a roughly $200 million expansion aimed at increasing capacity and long-term supply security, and is pursuing digital modernization through centralized electronic lab notebooks to improve data visibility across sites. Recent developments include industry recognition as a 2025 CDMO Leadership Award winner and the appointment of Giorgio Bertolini as General Manager for Italy, underscoring growth of its European footprint.
1-888-653-2347 
support@leadiq.com 
